Navigation Links
EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD
Date:11/5/2007

OAK BROOK, Ill., Nov. 5 /PRNewswire/ -- EPI-Q, Inc., a consulting firm providing outcomes research and health economics services to the global biopharmaceutical and healthcare industries, announces the addition of Anthony J. Vita, MD, MPH and Peter Herout, PharmD to their team of clinical professionals. The specialized background of these two practitioners will augment the capabilities EPI-Q is able to offer directly to those clients seeking to enhance the clinical outcomes and cost-effectiveness of patient care.

Both Dr. Herout and Dr. Vita will be responsible for providing clinical support and managing projects within their fields of clinical expertise. "Peter has significant expertise in critical care and cardiology adding to our ability to provide services to hospitals and managed care in both of these important areas. Anthony has clinical skills in mental health, a therapeutic category in which EPI-Q's business is rapidly expanding and his public health training provides additional depth to our methods group," stated EPI-Q President, Mark Jewell.

Dr. Herout has over 8 years experience as a clinical pharmacist. He has spent the majority of his professional career caring for a variety of critically ill patient populations. His most recent practice and research interests have included severe trauma, cardiothoracic surgery, sepsis, glycemic control, infectious diseases, renal replacement therapy, and nutrition support. Before joining EPI-Q, Dr. Herout spent 4 years with Advocate Christ Medical Center in Oak Lawn, Illinois. His contributions to the medical literature have included articles published in Critical Care Medicine and the American Journal of Health-System Pharmacy. He received his PharmD degree from the University of Illinois at Chicago, and completed one-year ASHP-accredited residencies in Pharmacy Practice and Critical Care.

Prior to joining EPI-Q, Dr. Vita worked as a resident physician at the University of Chicago, Department of Psychiatry for 3 years. He has also practiced in a variety of hospital settings including ICU, CCU, general medicine, general pediatrics, pediatric ICU, obstetrics, and neurology. Among the journals publishing Dr. Vita's works are The New England Journal of Medicine, The Journal of Pharmacology and Experimental Therapeutics, and The American Journal of Physiology. Dr. Vita received his Doctor of Medicine degree from Stanford University and Master of Public Health degree from Harvard University.

EPI-Q, Inc. (http://www.epi-q.com) provides life sciences companies and healthcare providers and payer organizations with evidence-based solutions that elucidate the value of medical technology and improve health outcomes and cost-effectiveness. EPI-Q's professionals have extensive expertise in medicine, pharmacy, epidemiology, biostatistics, economics, business and healthcare administration. In addition, many of these experts maintain academic affiliations, publish and present frequently on issues pertaining to quality improvement and outcomes management.

Contacts:

Mark Jewell, PhD Andrew M. Baker

President Vice President - Business Development

EPI-Q, Inc. EPI-Q, Inc.

Tel: 630.570.5505 Tel: 914.358.3264

Fax: 630.570.5506 Fax: 914.358.3265

Email: mark.jewell@epi-q.com Email: drew.baker@epi-q.com


'/>"/>
SOURCE EPI-Q, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... 2017  ArmaGen, Inc., today announced that it ... chief executive officer, as well as a member ... ArmaGen more than 17 years of executive management ... biotherapeutics and pharmaceuticals. "Mathias is ... and skillset necessary to lead ArmaGen to its ...
(Date:1/19/2017)... ... 19, 2017 , ... DaVita Clinical Research (DCR), ... and device development, and Prism Clinical Research , a leader in providing ... Verified Clinical Trials (VCT) has been selected by both companies as an ...
Breaking Biology Technology:
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
Breaking Biology News(10 mins):